Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Large-Vessel Involvement Is an Independent Risk Factor Predicting GCA Mortality

Carina Stanton  |  February 14, 2019

Giant cell arteritis (GCA), a large- and medium-vessel vasculitis, mainly involves the thoracic aorta and its branches. Few studies have evaluated the predictive factors for increased mortality in GCA patients. Recent findings of an Italian study of patients with incident temporal artery biopsy-proven GCA suggest large-vessel involvement at GCA diagnosis independently contributes to increased mortality. Also, the presence of polymyalgia rheumatica and isolated adventitial involvement or vasa vasorum vasculitis were associated with reduced mortality.1

According to histopathological patterns of the study patients, the differences in survival present new perspectives in predicting disease severity and mortality risk, says Pierluigi Macchioni, MD, a rheumatologist in the Department of Rheumatology, Azienda USL-IRCCS di Reggio Emilia, Italy, and an investigator in the study.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Previous studies evaluating mortality associated with GCA have concluded that mortality risk may be increased in some patients and may vary over time.2,3 Research has also demonstrated the value of imaging for better recognition and diagnosis of large-vessel involvement in GCA.4 However, none have considered temporal artery biopsy results or the presence of large-vessel involvement at disease presentation, Dr. Macchioni notes.

“The presence of these factors are more relevant for survival than cardiovascular risk factors,” he says.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Key Findings
The retrospective study analyzed data from 281 patients with incident temporal artery biopsy-proven GCA from the Reggio Emilia province of Northern Italy. Patients were diagnosed over a 26-year period, from 1986–2012. Investigators used multivariate analysis to analyze clinical, imaging and laboratory findings at diagnosis; pathological patterns of temporal artery biopsy; corticosteroid treatment and therapeutic outcomes; and traditional cardiovascular risk factors for predictive survival, including hypertension, hypercholesterolemia, hypertriglyceridemia, diabetes and smoking.

At the time of disease diagnosis, traditional cardiovascular risk factors and past history of cerebrovascular accidents and ischemic heart disease were not associated with a reduced survival in these patients. On histological examination of the temporal artery, patients with localized inflammation at only the adventitial layer were found to have significantly increased survival, which may represent a subset of patients with less severe disease and reduced mortality. Additionally, long-term GCA remission in this study was associated with reduced mortality, suggesting the efficacy of controlling inflammation.

Clinical Implications
Dr. Macchioni points to several implications for clinical practice that can be understood from identifying these survival predictors:

  • Determining the presence of large-vessel involvement at disease presentation using imaging, such as ultrasound or positron-emission tomography (PET) scan of the large vessels;
  • Defining the contemporary presence of polymyalgia rheumatica by asking the patient for signs and symptoms of this diseases and looking for typical alterations in shoulders or hips on ultrasound; and
  • Identifying the relevance of temporal artery biopsy, because patients with inflammation localized at only the adventitial layer have the best possibility of survival.

Two follow-up studies to this research are currently in progress. One is evaluating microRNA and cytokines and other inflammatory factors in biopsy specimens and blood of GCA patients as prognostic factors of survival and disease flares. The second study is investigating the evolution during follow-up of the large-vessel lesions found by PET scans and/or ultrasound as prognostic factors of survival.

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsVasculitis Tagged with:GCAgiant cell arteritis (GCA)mortality

Related Articles

    Two Inflammatory Conditions—Polymyalgia Rheumatica and Giant Cell Arteritis—Share Clinical Connection

    March 1, 2013

    Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) have common clinical and epidemiologic links, but they need not occur synchronously

    Atypical Giant Cell Arteritis Case Illustrates Diagnosis, Management Challenges

    Atypical Giant Cell Arteritis Case Illustrates Diagnosis, Management Challenges

    November 14, 2021

    Giant cell arteritis (GCA) is a granulomatous vasculitis of large- and medium-sized arteries, usually affecting the cranial branches of the aortic arch. It is the most common vasculitis, with the highest risk factor being age. Accurate diagnosis and prompt initiation of therapy are of great importance to prevent serious complications, with the most feared being…

    Updates on Giant Cell Arteritis

    March 19, 2018

    SAN DIEGO—Recent research tells us more about giant cell arteritis (GCA) to help rheumatologists more accurately diagnose and effectively treat patients with this type of vasculitis. On Nov. 6 at the ACR/ARHP Annual Meeting, three experts explored the latest findings on GCA pathogenesis, diagnostic approaches, imaging modalities and growing treatment options. GCA: What’s Really Happening?…

    Experts Discuss Proposed Giant Cell Arteritis Risk Tool

    April 26, 2018

    A proposed model to predict the risk of giant cell arteritis (GCA) prior to a temporal artery biopsy could help triage patients and guide decision making about the need for biopsy or monitoring (see Figure 1). There’s no specific biomarker for GCA, and GCA can be a “diagnostic conundrum, especially when it presents in an…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences